PRoHerpARDNCT07341386
Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases
At risk: Primary completion moved at least 8 months later.
See at-risk trials from University of Sao Paulo General Hospital
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Apr 1, 2027 to Dec 20, 2027
- Eligibility criteria expanded, about 5 words
- Secondary endpoints: details revised at 11 of 18 entries
- Publications: details revised at 3 of 3 entries
- Notable Recruitment opened
- Study sites: 0 to 1
- Start date changed from estimate of Apr 1, 2026 to Jun 25, 2026
Notable Start date: Jan 5, 2026 to Apr 1, 2026v2 Show 4 more changesShow less
- Eligibility criteria shortened, about 7 words
- Primary completion date: Dec 1, 2027 to Apr 1, 2027
- Study completion date: Mar 1, 2028 to Apr 1, 2028
- Secondary endpoints: details revised at 1 of 18 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (18)
Show 13 moreShow less
Arms and interventions
Patients with autoimmune rheumatic diseases and a history of recurrent HS will receive oral acyclovir 400 mg twice a day for 12 months. ARD patients will be randomly assigned in a 1:1 ratio, with the use of an automated Web and telephone system, to one of two subgroups: ACV or Placebo.
Patients with autoimmune rheumatic diseases and a history of recurrent HS will receive oral placebo twice a day for 12 months. ARD patients will be randomly assigned in a 1:1 ratio, with the use of an automated Web and telephone system, to one of two subgroups: ACV or Placebo.
Drugs: Acyclovir (ACV)
Other: Placebo
Sites
1 site in 1 country
- Reumatology division of Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo 05403-000São Paulo, São Paulo, Brazil